Upadacitinib, infliximab ‘clear frontrunners’ for rapid-onset relief in ulcerative colitis

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset and highest postinduction response of eight advanced therapies, according to results of a post-hoc analysis.The other therapies had a more gradual onset but exhibited strong efficacy by the end of induction.